Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients

NCT06126497 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Major Depressive Disorder

Interventions

DRUG: Ropanicant

Sponsor

Suven Life Sciences Limited